Status | Study |
Terminated |
Study Name: Study of the Effect of Zoledronate on Local Recurrence After Surgical Treatment of Giant Cell Tumors of Bone Zométa Condition: Giant Cell Tumors of Bone Date: 2011-06-28 Interventions: Drug: acid Zoledronic Treatment with zoledronic acid will be initiated during hospitalization, the day a |
Completed |
Study Name: Bioactive Glass Granules in Filling of Bone Defects Condition: Bone Tumors Date: 2011-02-21 Interventions: Device: Bioactive glass (SP53P4) Commercial resorbable bone graft substitute (Vioxid Ltd) |
Completed |
Study Name: Focused Ultrasound Surgery in the Treatment of Pain Resulting From Metastatic Bone Tumors With the ExAblate 2100 Conformal Bone System Condition: Bone Cancer Bone Metastases P Date: 2010-03-11 Interventions: Device: ExAblate 2100 Conformal Bone System |
Recruiting |
Study Name: Genomic Analysis of Pediatric Bone Tumors Condition: Bone Cancer Date: 2010-01-11 |
Completed |
Study Name: Bonefos and the Consumption of Analgesics Condition: Bone Neoplasms Date: 2009-05-25 Interventions: Drug: Bonefos (Clodronate, BAY94-8393) Patients in regular clinical practice receiving Bonefos according |
Terminated |
Study Name: Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT) Condition: Giant Cell Tumor of Bone Osteoclastoma Date: 2009-04-28 Interventions: Drug: Zoledronic acid 4 mg, monthly for 3 months followed by a 3-monthly schedule for up to one year aft |
Withdrawn |
Study Name: Using Mesenchymal Stem Cells to Fill Bone Void Defects in Patients With Benign Bone Lesions Condition: Bone Neoplasms Date: 2009-02-24 Interventions: Biological: Trinity multipotent stem cells |
Active, not recruiting |
Study Name: Comparison of Bioactive Glass and Beta-Tricalcium Phosphate as Bone Graft Substitute Condition: Bone Neoplasm Date: 2009-02-10 Interventions: Device: Bioactive glass Surgic |
Active, not recruiting |
Study Name: Study of Denosumab in Subjects With Giant Cell Tumor of Bone Condition: Cancer GCT Giant Cell Tumor of Bone Date: 2008-05-15 Interventions: Drug: Denosumab 120 mg administered subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 m |
Completed |
Study Name: Dynamic Contrast Enhanced MRI(DCE-MRI)of Bone Tumors Condition: Sarcoma Bone Tumor Date: 2008-01-10 Interventions: Other: DCE-MRI Patients will undergo DCE-MRI prior to, and |